Acanya is a U.S. prescription topical acne gel containing clindamycin phosphate 1.2% (equivalent to 1% clindamycin) and benzoyl peroxide 2.5%. This exact fixed-dose formula is different from plain clindamycin gel, other clindamycin/benzoyl peroxide concentrations and OTC benzoyl peroxide alone. For an overview of the drug families, see clindamycin combination products.
This page focuses on the brand identity and what a U.S. patient or pharmacist should verify: the labeled formulation, route, strength, package and prescription. It is deliberately separate from the ingredient-family guide and from other brands that can have different formulas. Drug labels establish regulatory and product facts but do not establish current stock at a named pharmacy.
Before filling a prescription, verify the exact brand or permitted generic, follow the prescriber's plan, and use a licensed dispensing pharmacy. The general prescription guide and online pharmacy verification checklist explain those access steps without implying an automatic prescription, medical interchangeability or guaranteed availability.
Acanya is labeled as clindamycin phosphate 1.2% with benzoyl peroxide 2.5%. The prescribing information also expresses the clindamycin content as 10 mg (1%) clindamycin per gram in phosphate form; these two label conventions should not be mistaken for different products. Identifying both ingredients and their concentrations is essential when a pharmacy listing abbreviates the name.
The label describes a prescription product for acne vulgaris and topical skin use. It is not oral clindamycin, vaginal clindamycin or an OTC benzoyl peroxide cleanser. A clinician should determine whether the fixed-dose combination suits the person and their acne treatment plan.
The U.S. label describes treatment of acne vulgaris in patients aged 12 years and older, for topical skin use. The actual prescribed directions and current dispensed label control use; a branded formula should not be converted into a home regimen using separate products.
Acanya combines a topical antibiotic with benzoyl peroxide in one product. Benzoyl peroxide is included in acne regimens partly because pairing it with a topical antibiotic helps address antibiotic-resistance concerns; however, product selection still depends on tolerability and clinical judgment.
Its 2.5% benzoyl peroxide concentration distinguishes Acanya from Onexton and other dual-ingredient gels. Percentages should be read directly from the complete pharmacy label, not inferred from the phrase “clindamycin/BPO”.
A pharmacy may show a generic clindamycin phosphate and benzoyl peroxide combination rather than the named brand. The pharmacist should verify matching active ingredients, labeled concentrations, formulation and any substitution requirements under applicable law.
A generic topical gel is not automatically a match just because it contains the same two ingredients. Differences in benzoyl peroxide concentration, dosage form or product labeling can be clinically important and should be reconciled with the prescription.
Confirm that the listing is for a topical prescription gel and that both concentrations appear in the intended order. Packaging descriptions can change, and a manufacturer’s drug listing cannot establish whether an individual pharmacy currently holds the product.
Ask the pharmacist to confirm brand-versus-generic status, dispensed quantity and the instructions printed on the pharmacy label. Do not assume that the package or pump pictured in an advertisement is the product that will actually be dispensed.
Acanya is a skin medication, and the prescription directions and manufacturer instructions control how it should be used. Contact with the eyes and other mucous membranes should be avoided. Irritation, dryness and other local reactions can occur.
Benzoyl peroxide can bleach hair and fabrics, and the combination can cause dryness, redness, and irritation. More importantly, the U.S. Acanya label lists a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis as a contraindication—not merely a routine caution. Its label also contraindicates use in people with hypersensitivity to clindamycin, lincomycin, benzoyl peroxide, or formulation components.
Acanya is not appropriate for everyone with acne. Its U.S. prescribing information identifies hypersensitivity to clindamycin, lincomycin, benzoyl peroxide or any formulation component as a contraindication. It also identifies a history of regional enteritis, ulcerative colitis or antibiotic-associated colitis as a contraindication. These are label exclusions, not simply optional questions.
Clindamycin applied to the skin can be absorbed systemically. Reports of diarrhea, including bloody diarrhea and colitis, explain why a topical product still warrants an accurate gastrointestinal history. Patients should contact their clinician if significant diarrhea develops and must not assume that a lower apparent systemic exposure makes the risk irrelevant.
This section concerns Acanya's actual labeled restrictions rather than a general rule about all acne gels. Patients should disclose prior reactions before a prescription is issued and read the specific dispensing information for any authorized alternative.
Acanya and Onexton use different benzoyl peroxide percentages; the products should not be exchanged independently. Likewise, a clindamycin/tretinoin gel or a triple-ingredient gel has a different active-ingredient profile.
For side-by-side formulation orientation, review the combination family rather than treating brand names as synonyms. A pharmacy should contact the prescriber when the ordered brand, concentration or package cannot be matched.
A valid prescription should specify the intended medicine and formulation, and the dispensing pharmacist should resolve any ambiguity between Acanya and other similarly named acne therapies. The online pharmacy guide explains how to check licensure, prescription requirements and access to a pharmacist rather than relying on marketing promises.
If the requested package is not available, ask the pharmacy what it can actually dispense and whether the prescriber must authorize an alternative. When comparing products, the related formulation comparison is useful for identifying differences, but does not authorize self-directed switching.
The amount a patient pays for Acanya can depend on brand versus generic status, package quantity, network status, formulary preferences, deductibles and dispensing terms. No static dollar quote can represent all pharmacies or plans. Start with topical clindamycin cost factors for a route-specific checklist.
Ask for a current quote for the exact brand or authorized substitute, with the same strength and package. Insurance verification covers tiers and prior authorization, while cash-pay discussions should focus on the total amount rather than unspecified discount promises.
This table separates the information printed on a U.S. prescription drug label from the additional facts a dispensing pharmacy must confirm. It should be used to frame questions, not to choose an antibiotic or retinoid regimen.
If the listing conflicts with the prescription on an ingredient, concentration or route, pause the transaction and ask a pharmacist or prescriber. Minor differences in brand spelling or packaging photography should not override the actual label.
| Check | Brand identity | What to ask the pharmacy |
|---|---|---|
| Ingredient formula | clindamycin phosphate 1.2% and benzoyl peroxide 2.5% | Does the dispensed item match the prescription? |
| Route | Topical skin use only | Is this a prescription acne gel, not oral or vaginal medication? |
| Brand/generic | Brand label; any substitutes require verification | Is the proposed alternative appropriate and permitted? |
| Pack and quantity | Manufacturer-labeled package; verify current presentation | Which package and quantity will be dispensed? |
| Cost | Plan or cash quote varies | What is the full current patient price? |
Obtain prompt medical advice if meaningful diarrhea, bloody diarrhea, severe abdominal cramps or serious skin irritation occurs. Severe allergic symptoms, including difficulty breathing or swelling of the face or throat, require emergency care. Systemic absorption has been documented with topical clindamycin, so the absence of an oral dose does not eliminate colitis-related risks.
Before dispensing, the prescriber and pharmacist should review inflammatory bowel disease history, antibiotic-associated colitis history, allergies and current acne products. If the exact product is not tolerated or is not available, do not substitute another concentration on your own. Review the clinical role of topical clindamycin and seek an individualized plan.
No. Acanya is a fixed-dose gel containing clindamycin phosphate 1.2% (equivalent to 1% clindamycin) and benzoyl peroxide 2.5%. Plain clindamycin gel lacks benzoyl peroxide; a substitute must be reviewed against the actual prescription.
Yes. The label specifies benzoyl peroxide 2.5% plus clindamycin phosphate 1.2%, equivalent to 1% clindamycin.
Not without review. The other brand or formulation may contain a different ingredient or concentration; the treating clinician and dispensing pharmacist should decide whether an alternative is appropriate.
No. A published label identifies a medicine and its approved information but does not provide real-time inventory for any pharmacy.
No. This is a topical skin product. It is not labeled for oral, eye or intravaginal administration.
Ask the pharmacist to verify the full ingredient formula, route, strength, package and regulatory substitution status against the prescription.
No. Coverage varies by plan, formulary, pharmacy network and individual benefits. Request a current quote or claim check.
No. Follow the individual prescription and product label. Excess application can increase irritation without establishing better acne control.
Ask the pharmacy to clarify the difference and contact the prescriber when the substitute is not clearly authorized or equivalent.
The label lists hypersensitivity to its ingredients or lincomycin and a history of regional enteritis, ulcerative colitis or antibiotic-associated colitis as contraindications. A clinician should review these before prescribing.